<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548228" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548228/" /><meta name="ncbi_pagename" content="Famotidine - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Famotidine - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Famotidine" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2018/01/25" /><meta name="citation_pmid" content="31643553" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548228/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Famotidine" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2018/01/25" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548228/" /><meta name="description" content="Famotidine is a histamine type 2 receptor antagonist (H2 blocker) which is commonly used for treatment of acid-peptic disease and heartburn. Famotidine has been linked to rare instances of clinically apparent acute liver injury." /><meta name="og:title" content="Famotidine" /><meta name="og:type" content="book" /><meta name="og:description" content="Famotidine is a histamine type 2 receptor antagonist (H2 blocker) which is commonly used for treatment of acid-peptic disease and heartburn. Famotidine has been linked to rare instances of clinically apparent acute liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548228/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Famotidine/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548228/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8814830465BA41000000000902026A.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548228_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548228_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Famciclovir/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Febuxostat/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548228_"><span class="title" itemprop="name">Famotidine</span></h1><p class="small">Last Update: <span itemprop="dateModified">January 25, 2018</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Famotidine.OVERVIEW"><h2 id="_Famotidine_OVERVIEW_">OVERVIEW</h2><div id="Famotidine.Introduction"><h3>Introduction</h3><p>Famotidine is a histamine type 2 receptor antagonist (H2 blocker) which is commonly used for treatment of acid-peptic disease and heartburn. Famotidine has been linked to rare instances of clinically apparent acute liver injury.</p></div><div id="Famotidine.Background"><h3>Background</h3><p>Famotidine (fam oh' ti deen) was the third H2 blocker introduced into clinical practice in the United States and is a commonly used agent for treatment of duodenal and gastric ulcer and gastroesophageal reflux disease. The H2 blockers are specific antagonists of the histamine type 2 receptor, which is found on the basolateral (antiluminal) membrane of gastric parietal cells. The binding of famotidine to the H2 receptor results in inhibition of acid production and secretion, and improvement in symptoms and signs of acid-peptic disease. The H2 blockers inhibit an early, &#x0201c;upstream&#x0201d; step in gastric acid production and are less potent that the proton pump inhibitors, which inhibit the final common step in acid secretion. Nevertheless, the H2 blockers inhibit 24 hour gastric acid production by about 70% and are most effective in blocking basal and nocturnal acid production. Famotidine was first approved for use in the United States in 1986 and more than 3 million prescriptions for it are filled yearly. Famotidine is now available both by prescription and over-the-counter. The listed indications for famotidine are duodenal and gastric ulcer disease, gastroesophageal reflux and prevention of stress ulcers. Famotidine is available in tablets of 20 and 40 mg in several generic forms and in parenteral forms under the brand name Pepcid. Over-the-counter formulations are typically gelcaps or tablets of 10 or 20 mg. Liquid solutions are also available for intravenous use. The typical recommended dose for therapy of peptic ulcer disease in adults is 40 mg once daily for 4 to 8 weeks and maintenance therapy of 20 mg daily. Lower, chronic and intermittent doses of famotidine are used for therapy of heartburn and indigestion. Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache and muscle aches. Famotidine is metabolized by the hepatic cytochrome P450 system, but has minimal inhibitory effects on the metabolism of other drugs, making it less likely to cause drug-drug interactions than cimetidine.</p></div><div id="Famotidine.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Chronic therapy with famotidine has been associated with minor elevations in serum aminotransferase levels in 1% to 4% of patients, but similar rates were reported in placebo recipients. The <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations are usually asymptomatic and transient, and may resolve without dose modification. Rare instances of clinically apparent liver injury have been reported in patients receiving famotidine, but few cases have been reported and clinical characteristics in published cases have varied in the time to onset and pattern of injury. Onset has ranged from 1 to 14 weeks and serum enzyme pattern has typically been hepatocellular. The injury resolves within 4 to 12 weeks of stopping famotidine. Immunoallergic features (rash, fever, eosinophilia) are uncommon, as is autoantibody formation.</p><p>Likelihood score: C (probable rare cause of clinically apparent liver injury).</p></div><div id="Famotidine.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>Famotidine is metabolized by the microsomal P450 drug metabolizing enzymes and injury may be the result of its activation to a toxic intermediate.</p></div><div id="Famotidine.Outcome_and_Management"><h3>Outcome and Management</h3><p>The hepatic injury caused by famotidine is usually rapidly reversible with stopping the medication (Case 1). Famotidine has not been definitively linked to cases of acute liver failure, chronic hepatitis, prolonged cholestasis or vanishing bile duct syndrome. The results of rechallenge have not been reported. There appears to be cross reactivity in hepatic injury with cimetidine (Case 2). If acid suppression is required, use of an unrelated proton pump inhibitor is probably prudent for patients with clinically apparent famotidine induced liver injury.</p><p>The H2 receptor blockers include cimetidine, famotidine, nizatidine, and ranitidine. Combined general references on the H2 receptor blockers are given together after this overview section, while specific references are provided in the separate section on each drug. See also the Proton Pump Inhibitors.</p><p>Drug Class: <a href="/books/n/livertox/AntiulcerAgents/">Antiulcer Agents</a></p><p>Other Drugs in the Subclass, <a href="/books/n/livertox/H2ReceptorBlockers/">Histamine Type 2 Receptor Antagonists</a>: <a href="/books/n/livertox/Cimetidine/">Cimetidine</a>, <a href="/books/n/livertox/Nizatidine/">Nizatidine</a>, <a href="/books/n/livertox/Ranitidine/">Ranitidine</a></p></div></div><div id="Famotidine.CASE_REPORTS"><h2 id="_Famotidine_CASE_REPORTS_">CASE REPORTS</h2><div id="Famotidine.Case_1._Mild_acute_liver_inju"><h3>Case 1. Mild acute liver injury due to famotidine.</h3><p>[Modified from: Ament PW, Roth JD, Fox CJ. Famotidine-induced mixed hepatocellular jaundice. Ann Pharmacother 1994; 28: 40-2. <a href="https://www.ncbi.nlm.nih.gov/pubmed/8123957" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>]</p><p>A 55 year old man with gastritis and abdominal pain was treated with ranitidine (150 mg twice daily) for 5 days and, when symptoms continued, was switched to famotidine (20 mg twice daily) and sucralfate (1 g four times daily). One week later he developed nausea and jaundice. He denied fever, chills, rash or pruritus. He had no history of liver disease, alcohol abuse or risk factors for viral hepatitis. He had been taking acetaminophen for the previous ten days (625 mg four times daily). On physical examination, he was jaundiced and had tenderness over the liver, but no fever, rash or signs of chronic liver disease. Laboratory results showed elevations in serum bilirubin with moderate elevations in serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> and alkaline phosphatase (Table). He tested negative for markers of viral hepatitis (A, B and C) and for autoimmune liver disease. Acetaminophen levels were normal (7 &#x000b5;g/mL: normal therapeutic range 10-20). Abdominal ultrasound showed no gallstones or evidence of biliary obstruction. Famotidine was stopped and he rapidly improved. A liver biopsy was not done. When seen five weeks later, all laboratory tests had returned to normal.</p><div id="Famotidine.Key_Points1"><h4>Key Points</h4><div id="Famotidine.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548228/table/Famotidine.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Famotidine.T1_lrgtbl__"><table><thead><tr><th id="hd_h_Famotidine.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Medication:</th><td rowspan="1" colspan="1" style="vertical-align:top;">Famotidine (40 mg daily)</td></tr></thead><tbody><tr><th headers="hd_h_Famotidine.T1_1_1_1_1" id="hd_b_Famotidine.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</th><td headers="hd_b_Famotidine.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Hepatocellular (R=6.1)</td></tr><tr><th headers="hd_h_Famotidine.T1_1_1_1_1" id="hd_b_Famotidine.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">Severity:</th><td headers="hd_b_Famotidine.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">3+ (jaundice, hospitalization)</td></tr><tr><th headers="hd_h_Famotidine.T1_1_1_1_1" id="hd_b_Famotidine.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Famotidine.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;">1 week</td></tr><tr><th headers="hd_h_Famotidine.T1_1_1_1_1" id="hd_b_Famotidine.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</th><td headers="hd_b_Famotidine.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">5 weeks</td></tr><tr><th headers="hd_h_Famotidine.T1_1_1_1_1" id="hd_b_Famotidine.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</th><td headers="hd_b_Famotidine.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Acetaminophen (~2.5 g daily)</td></tr></tbody></table></div></div></div><div id="Famotidine.Laboratory_Values1"><h4>Laboratory Values</h4><div id="Famotidine.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548228/table/Famotidine.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Famotidine.T2_lrgtbl__"><table><thead><tr><th id="hd_h_Famotidine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting</th><th id="hd_h_Famotidine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_Famotidine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> (U/L)</th><th id="hd_h_Famotidine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P (U/L)</th><th id="hd_h_Famotidine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a> (mg/dL)</th><th id="hd_h_Famotidine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Famotidine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Pre</td><td headers="hd_h_Famotidine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Famotidine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">34</td><td headers="hd_h_Famotidine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">67</td><td headers="hd_h_Famotidine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.9</td><td headers="hd_h_Famotidine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Famotidine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">7 days</td><td headers="hd_h_Famotidine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Famotidine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">305</td><td headers="hd_h_Famotidine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">182</td><td headers="hd_h_Famotidine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">7.1</td><td headers="hd_h_Famotidine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Admission</td></tr><tr><td headers="hd_h_Famotidine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">8 days</td><td headers="hd_h_Famotidine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">1 day</td><td headers="hd_h_Famotidine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">250</td><td headers="hd_h_Famotidine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">162</td><td headers="hd_h_Famotidine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">6.7</td><td headers="hd_h_Famotidine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Famotidine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">10 days</td><td headers="hd_h_Famotidine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">3 days</td><td headers="hd_h_Famotidine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">168</td><td headers="hd_h_Famotidine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">130</td><td headers="hd_h_Famotidine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">2.7</td><td headers="hd_h_Famotidine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Famotidine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">16 days</td><td headers="hd_h_Famotidine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">9 days</td><td headers="hd_h_Famotidine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">69</td><td headers="hd_h_Famotidine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">88</td><td headers="hd_h_Famotidine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.3</td><td headers="hd_h_Famotidine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Famotidine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">5 weeks</td><td headers="hd_h_Famotidine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td><td headers="hd_h_Famotidine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">26</td><td headers="hd_h_Famotidine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">61</td><td headers="hd_h_Famotidine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.1</td><td headers="hd_h_Famotidine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Famotidine.T2_1_1_1_1 hd_h_Famotidine.T2_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Famotidine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;25</b></td><td headers="hd_h_Famotidine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;90</b></td><td headers="hd_h_Famotidine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Famotidine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div><p>* <a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a> levels converted using formula of 17.1 &#x000b5;mol/L = 1.0 mg/dL.</p></div><div id="Famotidine.Comment1"><h4>Comment</h4><p>This patient developed a mild acute hepatitis 1 week after starting famotidine. While he had also been taking moderate doses of acetaminophen (2.5 g per day for 10 days), the pattern of injury was not typical of acetaminophen hepatotoxicity and acetaminophen levels were actually below the therapeutic range and well below the toxic range on admission. The pattern and course of the liver injury was quite typical of idiosyncratic drug induced liver injury and compatible with the type of injury that has been reported with H2 blockers with a short latency (1 week), a hepatocellular or mixed pattern of liver enzyme elevation and rapid recovery upon stopping. An issue is whether the 5 days of ranitidine may have caused or contributed to the injury and whether there may be cross sensitivity to hepatic injury among the various H2 blockers. Such cross sensitivity has been shown between famotidine and cimetidine (Case 2 below).</p></div></div><div id="Famotidine.Case_2._Acute_liver_injury_du"><h3>Case 2. Acute liver injury due to famotidine and recurrence due to cimetidine.</h3><p>[Modified from: Hashimoto F, Davis RL, Egli D. Hepatitis following treatments with famotidine and then cimetidine. Ann Pharmacother 1994; 28: 37-9. <a href="https://www.ncbi.nlm.nih.gov/pubmed/8123956" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>]</p><p>A 51 year old woman with symptomatic duodenal ulcer disease was treated with famotidine (40 mg daily), with subsequent improvement in epigastric pain and nausea, but with reappearance of abdominal discomfort followed by dark urine, itching and jaundice starting 3 weeks later. She denied fever or rash or history of drug allergy. She was overweight (BMI = 34.1), but had lost 2.3 kilograms in the previous week. She had no history of liver disease, alcohol abuse or risk factors for viral hepatitis. On examination, she was jaundiced and had mild hepatic tenderness but no peripheral signs of chronic liver disease. Laboratory testing showed total serum bilirubin of 5.0 (direct 4.1) mg/dL, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> 661 U/L, alkaline phosphatase 193 U/L, with normal serum albumin and prothrombin time (Table). Tests for hepatitis A, B and C were negative as were autoantibodies. Ultrasound of the abdomen showed an echogenic liver suggestive of steatosis, but no evidence of biliary obstruction. Famotidine was stopped and omeprazole (20 mg daily) substituted. She improved rapidly and liver tests were normal or near normal five weeks later, at which point cimetidine (800 mg daily) was substituted for omeprazole. One week later she redeveloped abdominal pain and nausea. The dose of cimetidine was increased, but over the next week she developed worsening symptoms and dark urine. Laboratory testing showed rises in serum bilirubin, ALT and alkaline phosphatase similar to those after famotidine therapy and cimetidine was stopped. Repeat evaluation revealed no evidence of viral hepatitis, autoimmune liver disease or biliary obstruction. She improved and was maintained on omeprazole therapy for her acid-peptic disease. In follow up 6 weeks later, liver tests had returned to normal or near-normal levels.</p><div id="Famotidine.Key_Points2"><h4>Key Points</h4><div id="Famotidine.T3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548228/table/Famotidine.T3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Famotidine.T3_lrgtbl__"><table><thead><tr><th id="hd_h_Famotidine.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Medication:</th><td rowspan="1" colspan="1" style="vertical-align:top;">Famotidine (40 mg daily), cimetidine (800 to 1200 mg daily)</td></tr></thead><tbody><tr><th headers="hd_h_Famotidine.T3_1_1_1_1" id="hd_b_Famotidine.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</th><td headers="hd_b_Famotidine.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Hepatocellular (R=14)</td></tr><tr><th headers="hd_h_Famotidine.T3_1_1_1_1" id="hd_b_Famotidine.T3_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">Severity:</th><td headers="hd_b_Famotidine.T3_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">3 (jaundice, hospitalization)</td></tr><tr><th headers="hd_h_Famotidine.T3_1_1_1_1" id="hd_b_Famotidine.T3_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Famotidine.T3_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;">3-4 weeks for famotidine, 1-2 weeks for cimetidine</td></tr><tr><th headers="hd_h_Famotidine.T3_1_1_1_1" id="hd_b_Famotidine.T3_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</th><td headers="hd_b_Famotidine.T3_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">6 weeks</td></tr><tr><th headers="hd_h_Famotidine.T3_1_1_1_1" id="hd_b_Famotidine.T3_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</th><td headers="hd_b_Famotidine.T3_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Antacids, occasional acetaminophen, oral contraceptives (many years)</td></tr></tbody></table></div></div></div><div id="Famotidine.Laboratory_Values2"><h4>Laboratory Values</h4><div id="Famotidine.T4" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548228/table/Famotidine.T4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Famotidine.T4_lrgtbl__"><table><thead><tr><th id="hd_h_Famotidine.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting</th><th id="hd_h_Famotidine.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_Famotidine.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> (U/L)</th><th id="hd_h_Famotidine.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P (U/L)</th><th id="hd_h_Famotidine.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a> (mg/dL)</th><th id="hd_h_Famotidine.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Famotidine.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Famotidine.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Famotidine.T4_1_1_1_3 hd_h_Famotidine.T4_1_1_1_4 hd_h_Famotidine.T4_1_1_1_5 hd_h_Famotidine.T4_1_1_1_6" colspan="4" rowspan="1" style="vertical-align:top;">Famotidine (40 mg/day) started</td></tr><tr><td headers="hd_h_Famotidine.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td><td headers="hd_h_Famotidine.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Famotidine.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">661</td><td headers="hd_h_Famotidine.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">193</td><td headers="hd_h_Famotidine.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">5.0</td><td headers="hd_h_Famotidine.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Famotidine stopped</td></tr><tr><td headers="hd_h_Famotidine.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">5 weeks</td><td headers="hd_h_Famotidine.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">1</td><td headers="hd_h_Famotidine.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">250</td><td headers="hd_h_Famotidine.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">250</td><td headers="hd_h_Famotidine.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.5</td><td headers="hd_h_Famotidine.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Symptoms resolved</td></tr><tr><td headers="hd_h_Famotidine.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">6 weeks</td><td headers="hd_h_Famotidine.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">2</td><td headers="hd_h_Famotidine.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">120</td><td headers="hd_h_Famotidine.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">150</td><td headers="hd_h_Famotidine.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.0</td><td headers="hd_h_Famotidine.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Famotidine.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">9 weeks</td><td headers="hd_h_Famotidine.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">5</td><td headers="hd_h_Famotidine.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">55</td><td headers="hd_h_Famotidine.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Famotidine.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Famotidine.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Cimetidine started</td></tr><tr><td headers="hd_h_Famotidine.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">11 [2] weeks</td><td headers="hd_h_Famotidine.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">[0]</td><td headers="hd_h_Famotidine.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">590</td><td headers="hd_h_Famotidine.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">180</td><td headers="hd_h_Famotidine.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">4.4</td><td headers="hd_h_Famotidine.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Cimetidine stopped</td></tr><tr><td headers="hd_h_Famotidine.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">[3] weeks</td><td headers="hd_h_Famotidine.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">[1] week</td><td headers="hd_h_Famotidine.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">430</td><td headers="hd_h_Famotidine.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">320</td><td headers="hd_h_Famotidine.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">8.2</td><td headers="hd_h_Famotidine.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Famotidine.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">[4] weeks</td><td headers="hd_h_Famotidine.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">[2] weeks</td><td headers="hd_h_Famotidine.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">190</td><td headers="hd_h_Famotidine.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">210</td><td headers="hd_h_Famotidine.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.2</td><td headers="hd_h_Famotidine.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Famotidine.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">[5] weeks</td><td headers="hd_h_Famotidine.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">[3] weeks</td><td headers="hd_h_Famotidine.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">90</td><td headers="hd_h_Famotidine.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">180</td><td headers="hd_h_Famotidine.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Famotidine.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Famotidine.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">[7] weeks</td><td headers="hd_h_Famotidine.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">[5] weeks</td><td headers="hd_h_Famotidine.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">48</td><td headers="hd_h_Famotidine.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">120</td><td headers="hd_h_Famotidine.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.0</td><td headers="hd_h_Famotidine.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Famotidine.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">[9] weeks</td><td headers="hd_h_Famotidine.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">[7] weeks</td><td headers="hd_h_Famotidine.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">44</td><td headers="hd_h_Famotidine.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">60</td><td headers="hd_h_Famotidine.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Famotidine.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Famotidine.T4_1_1_1_1 hd_h_Famotidine.T4_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;"><b>Normal Values*</b></td><td headers="hd_h_Famotidine.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;35</b></td><td headers="hd_h_Famotidine.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;150</b></td><td headers="hd_h_Famotidine.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Famotidine.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div><p>* Some values estimated from Figure 1, and bilirubin levels converted from &#x000b5;mol to mg/dL. Weeks in parentheses represent time after starting and stopping cimetidine.</p></div><div id="Famotidine.Comment2"><h4>Comment</h4><p>This patient appeared to develop a transient and self-limiting acute hepatitis-like injury after both famotidine and cimetidine therapy. The cross reactivity of these two agents was not suspected, based upon the lack of such cross reactivity to hepatic injury between cimetidine and ranitidine. However, in the case shown above, the recurrence was more rapid and perhaps slightly more severe with the &#x0201c;re-exposure&#x0201d; using cimetidine. Typical of H2 receptor blocker induced liver injury was the rapid recovery upon withdrawal. While liver biopsy was not done, in most such instances centrolobular necrosis with inflammation and mild cholestasis is found. This patient may have had mild underlying nonalcoholic fatty liver disease, but this is a common medical condition and unlikely played a role in the clinically apparent liver injury.</p></div></div></div><div id="Famotidine.PRODUCT_INFORMATION"><h2 id="_Famotidine_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Famotidine.BPI" class="box"><p><b> REPRESENTATIVE TRADE NAMES</b></p><p>Famotidine &#x02013; Generic, Pepcid&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antiulcer Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Famotidine" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Famotidine.CHEMICAL_FORMULA_AND_STRUCTUR"><h2 id="_Famotidine_CHEMICAL_FORMULA_AND_STRUCTUR_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Famotidine.T5" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548228/table/Famotidine.T5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Famotidine.T5_lrgtbl__"><table><thead><tr><th id="hd_h_Famotidine.T5_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Famotidine.T5_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Famotidine.T5_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Famotidine.T5_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Famotidine.T5_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Famotidine</td><td headers="hd_h_Famotidine.T5_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135011273" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">76824-35-6</a></td><td headers="hd_h_Famotidine.T5_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C8-H15-N7-O2-S3</td><td headers="hd_h_Famotidine.T5_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><div class="graphic"><img src="/books/NBK548228/bin/Famotidine_Structure.jpg" alt="Famotidine Chemical Structure" /></div></td></tr></tbody></table></div></div></div><div id="Famotidine.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Famotidine_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 25 January 2018</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Famotidine.R1">Zimmerman HJ. H2 Receptors antagonists. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 719-20.<div><i>(Expert review of hepatotoxicity published in 1999 states that cimetidine and ranitidine, despite enormous use, have been implicated in a small number of cases of hepatic injury, 39 for cimetidine, 35 for ranitidine and 1 for famotidine, all cases recovering and signs of hypersensitivity being rare).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R2">Wallace JL, Sharkey KA. Pharmacotherapy of gastric acidity, peptic ulcers, and gastroesophageal reflux disease. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1309-22.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R3">Black M. Hepatotoxic and hepatoprotective potential of histamine (H2)-receptor antagonists. Am J Med 1987; 83: 68-75.  [<a href="/pubmed/2892410" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2892410</span></a>]<div><i>(Review of hepatotoxicity of cimetidine and ranitidine and their potential role in ameliorating acetaminophen hepatotoxicity, perhaps via their inhibition of P450 activity).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R4">Dobrilla G, De Pretis G, Piazzi L, Boero A, Camarri E, Crespi M, Fontana G, et al. Comparison of once-daily bedtime administration of famotidine and ranitidine in the short-term treatment of duodenal ulcer. A multicenter, double-blind, controlled study. Scand J Gastroenterol Suppl 1987; 134: 21-8.  [<a href="/pubmed/2889255" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2889255</span></a>]<div><i>(Controlled trial comparing famotidine and ranitidine in 234 patients with duodenal ulcer disease; all had normal ALT levels at the end of therapy except for one [chronic alcoholic] patient who developed elevated aminotransferase levels on famotidine; no details given).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R5">Lewis JH. Hepatic effects of drugs used in the treatment of peptic ulcer disease. Am J Gastroenterol 1987; 82: 987-1003.  [<a href="/pubmed/2889354" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2889354</span></a>]<div><i>(Thorough review of hepatotoxicity of antiulcer medications; 10 published cases of hepatotoxicity due to cimetidine and 12 for ranitidine, none fatal and not all convincingly due to the medication; little information available on famotidine or nizatidine).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R6">Saigenji K, Fukutomi H, Nakazawa S. Famotidine: postmarketing clinical experience. Scand J Gastroenterol Suppl 1987; 134: 34-40.  [<a href="/pubmed/2889256" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2889256</span></a>]<div><i>(Postmarketing survey of 6436 Japanese patients on famotidine found side effects in &#x0003c;1% and liver test elevations in 33 [&#x0003c;0.5%], resolving in 11 of 25 who continued therapy).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R7">Ament PW, Roth JD, Fox CJ. Famotidine-induced mixed hepatocellular jaundice. Ann Pharmacother 1994; 28: 40-2.  [<a href="/pubmed/8123957" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8123957</span></a>]<div><i>(55 year old developed jaundice following treatment with 1 week of ranitidine and 1 week of famotidine [bilirubin 7.1 mg/dL, ALT 305 U/L, Alk P 182 U/L] with rapid resolution on stopping: Case 1).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R8">Hashimoto F, Davis RL, Egli D. Hepatitis following treatments with famotidine and then cimetidine. Ann Pharmacother 1994; 28: 37-9.  [<a href="/pubmed/8123956" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8123956</span></a>]<div><i>(51 year old developed pain and jaundice 3-4 weeks after starting famotidine [bilirubin 5 mg/dL, ALT 661 U/L, Alk P 193 U/L], recovering rapidly on omeprazole but with recurrence 1 week after starting cimetidine [bilirubin 8 mg/dL, ALT ~590 U/L, Alk P ~320 U/L], with rapid improvement on switching again to omeprazole: Case 2).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R9">Howden CW, Tytgat GN. The tolerability and safety profile of famotidine. Clin Ther 1996; 18: 36-54.  [<a href="/pubmed/8851452" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8851452</span></a>]<div><i>(Analysis of safety in 7483 patients in 27 trials of famotidine; side effects were uncommon [&#x0003c;1% for any specific symptom] and no more common than with placebo or comparator agents such as ranitidine; ALT elevations occurred in 2.2% on famotidine, 2.0% on ranitidine and 2.7% on placebo; only 1 patient discontinued famotidine because of elevation of liver tests).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R10">Garc&#x000ed;a Rodr&#x000ed;guez LA, Ruig&#x000f3;mez A, Jick H. A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom. Pharmacotherapy 1997; 17: 721-8.  [<a href="/pubmed/9250549" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9250549</span></a>]<div><i>(Combined analysis of 8 epidemiologic studies using the UK General Practice Research Database estimated incidence rates of acute liver injury to be highest for isoniazid and chlorpromazine [4 and 1.3 per 1000 users], intermediate for amoxicillin-clavulanate, cimetidine and ranitidine [2.3, 2.3 and 0.9 per 10,000], and lowest for trimethoprim/ sulfamethoxazole, omeprazole, amoxicillin and nonsteroidals [5.2, 4.3, 3.9 and 3.7 per 100,000]; famotidine not discussed).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R11">Garc&#x000ed;a Rodr&#x000ed;guez LA, Wallander MA, Stricker BH. The risk of acute liver injury associated with cimetidine and other acid-suppressing anti-ulcer drugs. Br J Clin Pharmacol 1997; 43: 183-8.  [<a href="/pmc/articles/PMC2042728/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2042728</span></a>] [<a href="/pubmed/9131951" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9131951</span></a>]<div><i>(Case control study in cohort of 100,000 users of antiulcer drugs in a UK general practice database; 33 cases of acute liver injury found, 12 on cimetidine for a relative risk [RR] of 5.5, 1 on omeprazole and 5 on ranitidine did not raise RR above baseline. Latency was &#x0003c;2 months in 80% of cases; most antiulcer drug cases had hepatocellular or mixed enzyme patterns [15 of 18]). </i></div></div></li><li><div class="bk_ref" id="Famotidine.R12">Sohn JH, Sohn YW, Jeon YC, Han DS, Hahm JS, Choi HS, Park KN, Kee CS. Three cases of hepatitis related to the use of famotidine and ranitidine. Korean J Hepatol 1998; 4: 194-9. Not in PubMed.<div><i>(Two cases of hepatotoxicity attributed to famotidine: 54 year old woman developed jaundice 6 weeks after starting famotidine [bilirubin 12 mg/dL, ALT 1520 U/L, Alk P 153], resolving within 2 months of stopping; a 45 year old man developed jaundice 6 weeks after restarting famotidine [bilirubin 14 mg/dL, ALT 58 U/L, Alk P 207 U/L], resolving within 3 months of stopping).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R13">Jim&#x000e9;nez-S&#x000e1;enz M, Arg&#x000fc;elles-Arias F, Herrer&#x000ed;as-Guti&#x000e9;rrez JM, Dur&#x000e1;n-Quintana JA. Acute cholestatic hepatitis in a child treated with famotidine. Am J Gastroenterol 2000; 95: 3665-6.  [<a href="/pubmed/11151926" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11151926</span></a>]<div><i>(13 year old developed jaundice 75 days after stopping a 30-day course of famotidine, with bilirubin rising from 9 to 26 mg/dL, ALT 1080 to 2400 U/L, Alk P 634 U/L, recovering in 2-3 months).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R14">Fisher AA, Le Couteur DG. Nephrotoxicity and hepatotoxicity of histamine H2 receptor antagonists. Drug Saf 2001; 24: 39-57.  [<a href="/pubmed/11219486" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11219486</span></a>]<div><i>(Review of renal and hepatic complications of H2 blocker therapy).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R15">Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug-induced liver injury in the United States. Liver Transpl 2004; 10: 1018-23.  [<a href="/pubmed/15390328" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15390328</span></a>]<div><i>(Among ~50,000 liver transplants reported to UNOS between 1990 and 2002, 270 [0.5%] were done for drug-induced acute liver failure, but none were attributed to an H2 blocker or proton pump inhibitor).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R16">de Abajo FJ, Montero D, Madurga M, Garc&#x000ed;a Rodr&#x000ed;guez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58: 71-80.  [<a href="/pmc/articles/PMC1884531/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1884531</span></a>] [<a href="/pubmed/15206996" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15206996</span></a>]<div><i>(Analysis of General Practice Research Database from UK on 1.6 million persons from 1994-2000 found 128 cases of drug-induced liver injury [2.4/100,000 person years]; 3 cases were attributed to cimetidine for an odds ratio of 2.0 compared to controls [n=5000] which was not statistically significant; famotidine not discussed).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R17">Bj&#x000f6;rnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 2005; 40: 1095-101.  [<a href="/pubmed/16165719" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16165719</span></a>]<div><i>(Survey of all cases of DILI with fatal outcome from Swedish Adverse Drug Reporting system from 1966-2002: 103 cases identified as highly probable, probable or possible, one case attributed to ranitidine and one to omeprazole, none attributed to famotidine).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R18">Sabat&#x000e9; M, Ib&#x000e1;&#x000f1;ez L, P&#x000e9;rez E, Vidal X, Buti M, Xiol X, Mas A, et al. Risk of acute liver injury associated with the use of drugs: a multicentre population survey. Aliment Pharmacol Ther 2007; 25: 1401-9.  [<a href="/pubmed/17539979" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17539979</span></a>]<div><i>(Population based survey of 126 cases of acute liver injury due to drugs between 1993-1999 in Spain; 8 were attributed to ranitidine alone [incidence 5.1/100,000 person-years] and 5 to omeprazole alone [2.1/100,000]; famotidine not mentioned).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R19">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34.  [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, 2 were attributed to ranitidine, none to famotidine or other antiulcer medications).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R20">Gupta N, Patel C, Panda M. Hepatitis following famotidine: a case report. Cases J 2009; 2: 89.  [<a href="/pmc/articles/PMC2640350/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2640350</span></a>] [<a href="/pubmed/19173722" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19173722</span></a>]<div><i>(47 year old man with chronic hepatitis C developed an acute rise in ALT within 3 days of laparoscopic cholecystectomy and 36 hours after starting famotidine [ALT 4755 U/L, AST 8466 U/L, bilirubin 2.5 mg/dL, INR 2.4], with rapid recovery within 10 days of stopping).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R21">Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F, Stricker BH, Sturkenboom MC. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. Br J Clin Pharmacol 2010; 70: 721-8.  [<a href="/pmc/articles/PMC2997312/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2997312</span></a>] [<a href="/pubmed/21039766" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21039766</span></a>]<div><i>(Worldwide pharmacovigilance database contained 9036 hepatic adverse drug reactions in children; no antiulcer medication was among the top 40 causes).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R22">Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76.  [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, but none were caused by antiulcer medications).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R23">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-25.  [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, but none were attributed to famotidine or other antiulcer medications).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R24">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Ann Hepatol 2014; 13: 231-9.  [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i> (Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, the most commonly implicated agents being nimesulide [n=53], cyproterone [n=18], nitrofurantoin [n=17] and antituberculosis drugs [n=13]; no case was linked to famotidine or other antiulcer agent).</i></div></div></li><li><div class="bk_ref" id="Famotidine.R25">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.e7.  [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 6 cases were attributed to antiulcer medications, 3 to ranitidine and 3 to PPIs, but none to famotidine).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548228</span><span class="label">PMID: <a href="/pubmed/31643553" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643553</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Famciclovir/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Febuxostat/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548228&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548228/?report=reader">PubReader</a></li><li><a href="/books/NBK548228/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548228" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548228" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Famotidine. [Updated 2018 Jan 25].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548228/pdf/Bookshelf_NBK548228.pdf">PDF version of this page</a> (130K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(Famotidine/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Famotidine: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Famotidine" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Famotidine: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4854206" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4854206" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4854206" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643264" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Histamine Type-2 Receptor Antagonists (H2 Blockers)</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Histamine Type-2 Receptor Antagonists (H2 Blockers)<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31644174" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ranitidine</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ranitidine<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643707" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Nizatidine</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Nizatidine<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643460" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Cimetidine</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Cimetidine<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/18600389" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease.</a><span class="source">[J Gastroenterol. 2008]</span><div class="brieflinkpop offscreen_noflow">A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hongo M, Kinoshita Y, Haruma K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Gastroenterol. 2008; 43(6):448-56. Epub 2008 Jul 4.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643553" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643553" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=6046829a739e6e7637e0bdd7">Famotidine - LiverTox</a><div class="ralinkpop offscreen_noflow">Famotidine - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T15:01:31-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal101&amp;ncbi_phid=CE8814830465BA41000000000902026A&amp;ncbi_session=CE881483046829A1_2306SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548228%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548228&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548228/&amp;ncbi_pagename=Famotidine - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE881483046829A1_2306SID /projects/books/PBooks@9.2 portal101 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>